ÂÜÀòÂÒÂ×

Harald Schnidar is the CEO, President, and Founder of SCARLETRED. Harald has over fifteen years of experience in the biologics and pharmaceutical industry. Prior to founding SCARLETRED, they were a Business Associate at APEIRON Biologics and Project Head for the clinical development of liposomal enclosed recombinant human Superoxide Dismutase (APN201). Before that, they were a Post Doctoral Research Assistant at Universität Salzburg where they worked on identifying tumor biomarkers in Multiple Myeloma cancer stem cells and on adipogenesis. Harald has also been a PhD. Project Employee in Science and a Scientific Project Employee at Universität Salzburg.

Harald Schnidar has a Mag.rer.nat. from Universität Salzburg in genetics, an MBA from the University of Westminster in business, management, and marketing, an MBA from the University of Toronto - Rotman School of Management in international economy, and an international executive MBA from SMBS - University of Salzburg Business School in economics. Harald also has a master's degree in business administration from Universität St. Gallen-Hochschule für Wirtschafts-, Rechts- und Sozialwissenschaften in business management and a PhD in molecular genetics from Universität Salzburg.

Some direct reports include Kathrin Schnidar - CFO, Stefan Schnidar - CTO.